COMMUNIQUÉS West-GlobeNewswire

Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment
25/06/2025
CMND-100 has the potential to provide an innovative and advanced treatment option for hundreds of millions of people around the world afflicted with Alcohol Use Disorder Vancouver, Canada, June 25, 2025 (GLOBE NEWSWIRE [...]
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
25/06/2025
Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA) Interim Phase 1 data show children with SMA [...]
Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)
25/06/2025
- End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer’s Disease Scheduled - - Applications for IND and Breakthrough Status Filed for Dementia with Lewy Bodies - PURCHASE, N.Y., June 25, 2025 (GLOBE NEWSWIRE [...]
Verano Unveils Bodega-Style Dispensary Experience at Zen Leaf Cave Creek in Phoenix
25/06/2025
Flipping the script on the traditional dispensary format, the new bodega-style shopping experience offers customers the freedom to browse and select their favorite items directly from shelves featuring one of the [...]
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
25/06/2025
Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan Feld, Ed Gane, Anna Lok, Mark Sulkowski and Man-Fung Yuen join Arbutus Scientific Advisory [...]
Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer
25/06/2025
Phase 1/2a clinical trial currently supported by a $3.0 million grant from the U.S. Department of Defense Trial will enroll children with high grade glioma and ependymoma HOUSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Plus [...]
SmartVascular Dx™ Test: Enhancing Vascular Care in the Midwest
25/06/2025
IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC ., (“MSL” or “the Company”), is a leading developer of precision diagnostic tests that address unmet clinical needs, is proud to announce [...]
First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial
25/06/2025
The first CLARITY patient was enrolled at the Texas Back Institute, a world leader in advancing spine technology, science, and education, as well as patient care CLARITY is a randomized clinical trial designed to [...]
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
25/06/2025
REYKJAVIK, ICELAND, PISCATAWAY, NEW JERSEY AND LONDON, UK (June 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients [...]
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)
25/06/2025
REYKJAVIK, Iceland and PISCATAWAY, N.J. and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for [...]
Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)
25/06/2025
The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease [...]
Actimed Therapeutics Enrolls First Patients in Phase 2a PROACT Study Programme to Assess S-pindolol benzoate in Obese Patients During and Post-GLP-1 Agonist Therapy
25/06/2025
Two-part clinical study programme to evaluate change in lean and fat mass in patients receiving two different doses of S-pindolol benzoate whilst 1) receiving the GLP-1 agonist semaglutide; and 2) after cessation of [...]
Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director
25/06/2025
Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director Egham, UK – 25 June 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company developing [...]
OSE Immunotherapeutics provides an update on ongoing proceedings
25/06/2025
OSE Immunotherapeutics provides an update on ongoing proceedings Nantes, June 25 th , 2025, 8:00 a.m. - OSE Immunotherapeutics SA ( ISIN: FR0012127173; Mnemo: OSE), announces that, following the hearing on June 24th, [...]
OSE Immunotherapeutics met à jour l’information sur les procédures en cours
25/06/2025
OSE Immunotherapeutics met à jour l’information sur les procédures en cours NANTES, France, 25 juin 2025, 8 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) annonce qu’à la suite de l’audience le [...]
LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park
25/06/2025
LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park London, 25 June 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in [...]
Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds
25/06/2025
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June 25, 2025 Idorsia Ltd (SIX: IDIA) today announced the launch of the repurchase offer to the holders of its outstanding CHF 200 million convertible [...]
Addex Shareholders Approve All Resolutions at Annual General Meeting
25/06/2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug [...]
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
25/06/2025
Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active [...]

Pages